Tag Archives: Andrew D’silva

Viewray (VRAY) Gets a Hold Rating from B.Riley FBR

B.Riley FBR analyst Andrew D’silva maintained a Hold rating on Viewray (VRAY – Research Report) today and set a price target of $2.50. The company’s shares closed last Tuesday at $2.05, close to its 52-week low of $1.11. According to

B.Riley FBR Reaffirms Their Buy Rating on Geron (GERN)

In a report released today, Andrew D’silva from B.Riley FBR maintained a Buy rating on Geron (GERN – Research Report), with a price target of $4.00. The company’s shares closed last Friday at $1.93. According to TipRanks.com, D’silva is a

EDAP TMS (EDAP) Receives a Buy from B.Riley FBR

In a report released today, Andrew D’silva from B.Riley FBR maintained a Buy rating on EDAP TMS (EDAP – Research Report), with a price target of $5.50. The company’s shares closed last Tuesday at $2.81. According to TipRanks.com, D’silva is

B.Riley FBR Reaffirms Their Buy Rating on Cytosorbents (CTSO)

B.Riley FBR analyst Andrew D’silva maintained a Buy rating on Cytosorbents (CTSO – Research Report) today and set a price target of $16.00. The company’s shares closed last Thursday at $8.77. According to TipRanks.com, D’silva is a 3-star analyst with

Analysts Offer Insights on Healthcare Companies: Geron (NASDAQ: GERN) and Zynex (NASDAQ: ZYXI)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Geron (GERN – Research Report) and Zynex (ZYXI – Research Report) with bullish sentiments. Geron (GERN) B.Riley FBR analyst Andrew D’silva maintained

B.Riley FBR Thinks Cumberland Pharmaceuticals’ Stock is Going to Recover

In a report released today, Andrew D’silva from B.Riley FBR maintained a Buy rating on Cumberland Pharmaceuticals (CPIX – Research Report), with a price target of $9.75. The company’s shares closed last Wednesday at $3.75, close to its 52-week low